诺为泰（Novotech）：2023血脂异常：全球临床试验概况报告（中译版）（19页）.pdf

1、novotech-OCTOBER 5,2023Dyslipidaemia Global Clinical trial landscape(2023)WHO 2008 estimates indicate that Europe and America have higher hypercholesterolemia rates than Southeast Asia and AfricaIn the Asia Pacific regions,Japan had a relatively elevated prevalence of high total cholesterol(TC)Malay

2、sia reported a notably high TC prevalence between 2006 and 2012The Philippines had alarmingly high TC and low HDL-C levels in 2013,emphasizing the necessity for region-specific strategies to tackle lipid-related health concernsAPAC contributed 65%of Dyslipidaemia trials,notably driven by Mainland Ch

3、ina and South KoreaUS and Europe conducted 30%of Dyslipidaemia trials;the US led in North America,UK in EuropeAPAC has not only demonstrated considerably shorter recruitment durations but has also shown notably faster patient recruitment ratesEurope led with substantial progress and favourable resea

4、rch,while APAC and North America progressed steadily but more slowlyDYSLIPIDAEMIAGLOBAL CLINICAL TRIAL LANDSCAPE The content of this publication is proprietary to Novotech Health Holdings.No part of this publication may be reproduced,distributed,or transmitted in any form or by any means,including p

5、hotocopying,recording,or other electronic or mechanical methods,without the prior written permission of Novotech except in the case of quotations embodied in reviews and non-commercial uses.Please note that this copyright statement applies specifically to this publication and its content and does no

6、t extend to other materials or intellectual property owned by Novotech.Any unauthorized reproduction or distribution of this publication or any portion thereof may result in legal action taken by Novotech to protect its rights.For permissions or inquiries,please contact:communicationsnovotech-Dyslip